<DOC>
	<DOC>NCT01033747</DOC>
	<brief_summary>The purpose of this study is to assess the safety and the effects on liver iron of Deferasirox when given for a long treatment period in patients with transfusion dependent iron overload.</brief_summary>
	<brief_title>Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>Patients Currently participating in the 9month comparative prolongation of extension phase of the original study. Patients currently participating in the foodeffect substudy, according to amendment 3. Ability to provide written informed consent prior to participation in this noncomparative extension study. Female patients sexually active must use doublebarrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation. Body weight of at least 35 kg. Pregnant or breastfeeding patients. History of noncompliance to medical regimens and patients who are considered potentially unreliable. Proteinuria &gt; 300 mg/L second void morning urine. Patients with serum creatinine above the upper limit normal. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>iron overload</keyword>
	<keyword>iron chelation therapy</keyword>
	<keyword>B-thalassemia</keyword>
</DOC>